List of Excipients in Branded Drug ADENOSINE INJECTION, 6MG/2ML (3MG/ML) VIAL

Generic Drugs Containing ADENOSINE INJECTION, 6MG/2ML (3MG/ML) VIAL

Company	Ingredient	NDC	Excipient
HF Acquisition Co LLC DBA Health First	adenosine injection, 6mg/2ml (3mg/ml) vial	51662-1201	SODIUM CHLORIDE
HF Acquisition Co LLC DBA Health First	adenosine injection, 6mg/2ml (3mg/ml) vial	51662-1201	WATER

What are the Most Frequently-Used Excipients in ADENOSINE INJECTION, 6MG/2ML (3MG/ML) VIAL?

# Of NDCs	Excipient
1	SODIUM CHLORIDE
1	WATER

Excipient Strategy and Commercial Opportunities for Adenosine Injection 6 mg/2 mL Vial

Last updated: August 24, 2026

Adenosine injection 6 mg/2 mL, equivalent to 3 mg/mL, is a mature generic injectable used for rapid conversion of paroxysmal supraventricular tachycardia and for pharmacologic cardiac stress testing. The standard formulation is intentionally simple: adenosine in Water for Injection with sodium chloride for isotonicity. Commercial opportunity is therefore concentrated in presentation, stability, supply reliability, administration safety, and differentiated delivery systems rather than in conventional excipient innovation.

What is the formulation of adenosine injection 6 mg/2 mL?

A representative adenosine injection formulation contains:

Component	Typical function
Adenosine	Active pharmaceutical ingredient
Sodium chloride	Tonicity adjustment
Water for Injection	Vehicle
pH adjustment agents, where applicable	pH control

Many U.S. labels describe the product as a sterile, preservative-free solution containing 3 mg/mL adenosine and 9 mg/mL sodium chloride in Water for Injection. The resulting sodium chloride concentration is approximately 0.9%, consistent with an isotonic injectable solution. Product-specific labeling controls the definitive qualitative and quantitative composition. [1]

The standard 6 mg/2 mL vial is intended for rapid intravenous administration. Adenosine has an extremely short plasma half-life, generally less than 10 seconds, which makes rapid bolus delivery and immediate saline flushing operationally important. [2]

What excipients are normally used?

The excipient platform is usually limited to sodium chloride and Water for Injection. This simplicity reflects several technical and regulatory factors:

• Adenosine is highly water-soluble.
• The product is administered intravenously and must minimize excipient-related toxicity.
• Preservatives are generally undesirable in emergency-use products.
• The short dosing interval limits the need for prolonged in-use stability.
• Sodium chloride provides a familiar and broadly accepted isotonicity strategy.

A formulation containing multiple buffers, surfactants, antioxidants, or antimicrobial preservatives would need a clear technical justification because those components could increase compatibility, toxicity, particulate, or regulatory risks without improving the core clinical function.

What are the critical quality attributes for adenosine injection?

The key quality attributes are sterility, assay, purity, particulate control, pH, osmolality, visible appearance, container closure integrity, and stability.

Quality attribute	Commercial relevance
Adenosine assay	Ensures dose accuracy during rapid emergency administration
Related substances	Controls degradation products
pH	Affects stability, tolerability, and container compatibility
Osmolality	Supports intravenous tolerability
Particulate matter	Critical for injectable safety
Sterility	Mandatory for parenteral use
Endotoxins	Controls pyrogenic risk
Container closure integrity	Protects against contamination and moisture ingress
Light and temperature stability	Determines storage and distribution requirements

Adenosine is susceptible to degradation through hydrolysis and oxidative pathways. The formulation strategy should therefore control water quality, oxygen exposure, headspace, light exposure, sterilization conditions, and processing hold times.

How does pH affect the formulation?

pH must balance chemical stability, solubility, intravenous tolerability, and container compatibility. Excessively acidic or alkaline conditions can increase degradation or injection-site discomfort. The development target should be based on the product’s demonstrated stability profile rather than on broad pH adjustment.

Buffer selection is a potential technical differentiator, but a buffer is not automatically commercially advantageous. A buffer can alter degradation kinetics, interact with elastomeric closures, increase ionic strength, or complicate compatibility with administration equipment.

Is a preservative appropriate?

A preservative-free, single-dose presentation is generally the strongest commercial fit for emergency cardiovascular use. Preservatives may create concerns regarding intravenous exposure, neonatal use, repeated withdrawals, and institutional formulary acceptance. A multidose format would require a stronger justification and more extensive antimicrobial effectiveness, in-use stability, and labeling work.

What commercial opportunities exist in the excipient strategy?

The largest opportunities are formulation-adjacent. The base solution is mature, but manufacturers can improve the total product through packaging, administration, logistics, and supply performance.

1. Ready-to-administer presentations

Adenosine is often administered in urgent settings where dose preparation and timing affect clinical workflow. A ready-to-administer syringe can reduce the number of manipulation steps compared with withdrawing a dose from a vial and preparing a saline flush.

Potential product configurations include:

• 6 mg/2 mL prefilled syringe
• 12 mg/4 mL prefilled syringe
• Dual-syringe adenosine and saline systems
• Unit-dose emergency kits
• Barcoded syringes for automated medication administration systems

A prefilled syringe would not necessarily require a new excipient system. Its value would come from dose accuracy, reduced preparation time, lower contamination risk, and improved inventory control.

2. Enhanced stability packaging

Adenosine products can be differentiated through packaging that reduces light and oxygen exposure. Relevant approaches include:

• Amber or light-protective primary containers
• Low-oxygen headspace filling
• Oxygen-barrier secondary packaging
• Optimized elastomeric closures
• Reduced adsorption and extractables profiles
• Container closure systems validated for low-volume emergency injectables

Packaging claims must be supported by comparative stability and extractables and leachables data. The technical barrier is higher for prefilled syringes than for conventional glass vials because the formulation contacts additional materials.

3. Low-volume vial optimization

The 6 mg/2 mL vial is a small-volume presentation. Commercial value can be created by improving:

• Fill-volume accuracy
• Vial visibility and label readability
• Break-resistant packaging
• Ease of withdrawal
• Compatibility with automated dispensing cabinets
• Unit-dose carton configuration
• Waste reduction from overfill

Hospitals often purchase injectable drugs based on total cost of use rather than acquisition price alone. A vial that reduces preparation time or medication waste can compete effectively even where the active ingredient and excipients are identical.

4. Sodium and tonicity optimization

Sodium chloride is a conventional excipient, but its concentration can be assessed against product-specific osmolality and tolerability requirements. A lower-sodium or alternative tonicity strategy could have value in selected populations, but the commercial market is unlikely to reward a formulation change unless it produces a clinically meaningful or operational advantage.

Potential development rationales could include:

• Reduced sodium exposure in repeated stress-testing protocols
• Improved compatibility with specific infusion systems
• Lower osmolality
• More consistent administration through small-bore access devices

These concepts would require clinical and regulatory justification. The standard isotonic approach remains the lowest-risk benchmark.

What patents protect adenosine injection formulations?

Adenosine itself is an established endogenous nucleoside and is not protected by a commercially relevant composition-of-matter patent for the standard injectable product. Core patent barriers for adenosine injection are therefore limited.

Potential intellectual-property categories include:

IP category	Relevance to standard 6 mg/2 mL vial
Adenosine composition-of-matter patents	Generally expired or not relevant
Basic sodium chloride formulation patents	Low likelihood of enforceable protection
Method-of-use patents	Limited for established indications
Prefilled syringe patents	Potentially relevant
Dual-chamber or flush-device patents	Potentially relevant
Stability and packaging patents	Possible for specific configurations
Manufacturing-process patents	Possible but generally narrow
Device combination patents	Relevant to differentiated delivery systems

A manufacturer seeking durable exclusivity would likely need to claim a specific device, container closure system, stability profile, manufacturing process, or administration configuration. Broad claims covering adenosine in saline would face substantial prior-art and obviousness challenges.

What is the Orange Book status of adenosine injection?

Adenosine injection is a mature generic product category. FDA-approved products are primarily marketed through abbreviated new drug applications rather than through active innovation-based exclusivity.

The principal regulatory characteristics are:

• Generic injectable products are generally approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act.
• Product-specific patent information must be assessed through the current FDA Orange Book and the applicable reference-listed drug record.
• Standard generic adenosine injection products generally do not depend on a current composition-of-matter patent.
• Any listed patents would be evaluated for expiration, certification status, and relevance to the specific dosage form and use. [3]

Because the product is an injectable solution with a simple formulation, a conventional ANDA is typically more commercially efficient than a 505(b)(2) strategy unless the applicant is introducing a meaningful formulation, device, or administration difference.

When does adenosine injection lose exclusivity?

The standard adenosine injection market has already passed the principal exclusivity period associated with the original branded product. The relevant commercial issue is not loss of originator exclusivity but the ability to maintain pricing and supply performance in a crowded generic market.

For a new entrant, exclusivity could arise from:

• 180-day first-to-file generic exclusivity, if applicable
• Orphan-drug exclusivity, which is generally not the central pathway for this product
• New drug product exclusivity associated with a qualifying reformulation
• Device or delivery-system protection
• Contractual hospital or group-purchasing arrangements

A plain generic adenosine injection is unlikely to sustain premium pricing without manufacturing reliability, presentation differentiation, or distribution advantages.

Are Paragraph IV challenges relevant to adenosine injection?

Paragraph IV litigation is likely to have limited commercial significance for the standard 3 mg/mL vial because the principal product category is old and genericized. Paragraph IV risk becomes more relevant if a manufacturer develops:

• A newly patented prefilled syringe
• A protected dual-chamber delivery system
• A novel stability-enhancing formulation
• A patented method for a new diagnostic or therapeutic use
• A combination product with an administration device

The commercial value of such patents would depend on whether the claims cover the approved product as sold, not merely a laboratory formulation or optional manufacturing step.

What FDA regulatory pathway applies to a new adenosine injection?

Conventional generic vial

A standard adenosine injection containing the same active ingredient, strength, dosage form, route, and inactive ingredients as the reference product is generally suited to an ANDA. The applicant must demonstrate pharmaceutical equivalence and bioequivalence through the applicable injectable-product framework. [4]

For an aqueous injectable solution, the regulatory focus typically includes:

• Same active ingredient and concentration
• Same route of administration
• Equivalent dosage form
• Sterility and endotoxin control
• Comparative physicochemical characterization
• Inactive-ingredient justification
• Container closure and stability data

Reformulated or device-enabled product

A product with a materially different excipient system, prefilled device, or combined saline flush may require a 505(b)(2) application or a combination-product assessment. The pathway depends on the extent of the change and the regulatory reliance on prior FDA findings.

A 505(b)(2) strategy is commercially justified only where the new product offers a defensible advantage, such as lower preparation risk, longer stability, reduced waste, or a new clinical use.

What generic entry risks exist?

Generic entry risk is high for the conventional vial because the product has:

• An old active ingredient
• A simple aqueous formulation
• Limited formulation complexity
• No meaningful biosimilar barrier
• Familiar manufacturing technology
• Established clinical use
• Multiple potential sterile injectable manufacturers

Competitive risks include price erosion, shortages caused by manufacturing interruptions, and substitution through hospital purchasing contracts.

The principal barriers are operational rather than patent-based:

• Sterile manufacturing capacity
• FDA inspection readiness
• Reliable glass vial and elastomer supply
• Low-volume fill-finish economics
• Particulate and sterility control
• Ability to meet hospital demand during shortages
• Contracting access through group purchasing organizations

Which companies are challenging or competing with standard adenosine injection?

The competitive field includes branded legacy products, generic sterile injectable manufacturers, contract manufacturers, and companies offering prefilled emergency syringes. Competition is usually determined by FDA approval status, current supply, NDC availability, hospital contracts, and shortage history.

Relevant competitor categories include:

1. Generic vial suppliers with 6 mg/2 mL presentations.
2. Suppliers offering 12 mg/4 mL products for dose escalation.
3. Prefilled syringe manufacturers.
4. Specialty injectable companies focused on emergency medicine.
5. Contract manufacturers with small-volume sterile fill-finish capacity.

Manufacturer-level conclusions require a current NDC and FDA approval review because market participation changes through discontinuations, acquisitions, and shortage-related supply shifts.

How does adenosine compare with competing pharmacologic stress agents?

Adenosine competes clinically with regadenoson, dipyridamole, and dobutamine in cardiac stress testing, although these products do not share the same excipient or administration profile.

Product	Active ingredient	Typical commercial differentiation
Adenosine injection	Adenosine	Low-cost, established, rapid-onset infusion or bolus use
Regadenoson injection	Regadenoson	Fixed-dose bolus and simpler administration
Dipyridamole injection	Dipyridamole	Alternative vasodilator stress agent
Dobutamine injection	Dobutamine	Different pharmacologic mechanism and stress-testing role

Regadenoson has a meaningful administration advantage because it is delivered as a fixed-dose bolus, while adenosine often requires rapid administration and close procedural coordination. Adenosine retains value through low acquisition cost and established emergency use.

What manufacturing and IP barriers matter most?

The strongest defensible position is likely to come from a combined product strategy rather than an excipient-only patent.

Potentially protectable combinations include:

• Adenosine solution plus a validated low-adsorption syringe
• Adenosine vial packaged with an integrated saline flush
• Oxygen-controlled filling and packaging
• A stability profile supporting extended storage
• A ready-to-administer emergency kit
• A proprietary automated dispensing configuration
• A specific container closure system that reduces particulate or leachables

Manufacturing know-how may be more valuable than patent protection. Sterile processing, fill-volume control, oxygen management, and supplier qualification can create practical barriers that are difficult for new entrants to replicate quickly.

What is the revenue opportunity for differentiated adenosine injection?

The standard vial is a volume product with limited per-unit pricing power. Revenue expansion is more likely through adjacent products:

• Premium prefilled syringes
• Emergency department and catheterization laboratory kits
• Cardiology stress-testing kits
• Hospital-system contracts
• Regional shortage-resilient supply
• Private-label sterile injectable partnerships
• International registration of the same platform

A differentiated presentation can shift the purchasing decision from unit price to total workflow cost. The most credible value proposition is reduced preparation time and medication-handling risk, not a marginal change in sodium chloride concentration.

Key Takeaways

• Adenosine injection 6 mg/2 mL is normally a simple, preservative-free aqueous solution containing adenosine, sodium chloride, and Water for Injection.
• The core formulation has limited patent potential because adenosine injection is an old, genericized product.
• The strongest commercial opportunities are prefilled syringes, emergency kits, stability-enhanced packaging, and supply reliability.
• A conventional product is generally suited to an ANDA; a materially differentiated formulation or device may require a 505(b)(2) pathway.
• Paragraph IV and biosimilar risks are limited for the standard vial.
• The principal barriers are sterile manufacturing, fill-finish capacity, quality control, packaging compatibility, and hospital contracting.
• A premium product must demonstrate operational value, especially lower preparation time, reduced waste, or improved administration safety.

FAQs About Adenosine Injection Excipient and Commercial Strategy

Can sodium chloride be removed from adenosine injection?

Possibly, but the resulting formulation would require validation of osmolality, stability, intravenous tolerability, and container compatibility. Removing sodium chloride would not automatically create a commercial advantage.

Is adenosine injection a biologic or biosimilar product?

No. Adenosine injection is a chemically defined small-molecule drug. Biosimilar approval and biosimilar interchangeability rules do not apply.

Can a prefilled adenosine syringe receive new market exclusivity?

A prefilled syringe may support device or formulation patents, and a qualifying new drug application may create regulatory exclusivity. Exclusivity depends on the approved claims and applicable FDA pathway.

What excipient is most important for adenosine injection stability?

Water quality, oxygen control, pH management, and container compatibility are usually more important than adding a complex excipient system. Sodium chloride primarily supports tonicity.

Is a 12 mg/4 mL adenosine product commercially distinct from a 6 mg/2 mL vial?

It can be operationally distinct because it supports dose escalation and inventory standardization, but both presentations contain the same 3 mg/mL concentration. Commercial differentiation depends on workflow, packaging, and purchasing requirements.

References

1. U.S. National Library of Medicine. (2024). Adenosine injection, solution: DailyMed labeling. DailyMed.

2. American Heart Association. (2020). 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation, 142(Suppl. 2).

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2023). Generic drug development and approval process. FDA.